Mechanistic investigations should focus on longitudinal monitoring of PBIBs during treatment to clarify their role in predicting therapeutic resistance, while experimental models (e.g., in vitro or animal studies) could explore interventions targeting inflammation-immune crosstalk, such as TGF-β or IL-6/STAT3 pathway inhibition, to improve clinical outcomes in lip cancer. The gene discussed is STAT3; the disease is lip cancer.